UPMC Hillman Cancer Center

The UPMC Hillman Cancer Center , previously titled the University of Pittsburgh Cancer Institute , is a National Cancer Institute -designated Comprehensive Cancer Center located in the Hillman Cancer Center in the Shadyside neighborhood of Pittsburgh, Pennsylvania, United States. The only NCI-designated cancer center in Western Pennsylvania, Hillman is composed of collaborative academic and research efforts between the University of Pittsburgh, the University of Pittsburgh Medical Center , and Carnegie Mellon University. Hillman provides clinical cancer care to some 74,000 patients treated at its facilities at both the flagship Hillman Cancer Center location in the Shadyside neighborhood of Pittsburgh and at dozens of UPMC-affiliated sites throughout Pennsylvania, New York, Ohio, and a growing list of overseas locations. Founded in 1984, Hillman became the youngest cancer center in history to achieve NCI-designation, and as of 2007 received nearly $200 million in funding from the National Cancer Institute ranking it in the top ten of all cancer research institutes.
The Pittsburgh Cancer Institute was founded in 1984 under the direction of Ronald B. Herberman, MD. Hillman Cancer Center was formed from a partnership with Pittsburgh Cancer Institute and private physicians in 2002. Hillman remains the only NCI-designated Comprehensive Cancer Center in Western Pennsylvania, and today is composed of 625 research faculty members specializing in disciplines ranging from cancer prevention and early detection to novel therapeutic discovery, survivorship, and end of life care. Most Hillman faculty maintain academic appointments at the University of Pittsburgh and physician-scientists have their clinical appointments through UPMC hospitals. However, some Hillman members are affiliated with the neighboring Carnegie Mellon University. Four target research areas of molecular and medical oncology at the institute include 1) the biological basis of cancer development and progression; 2) identification of new biomarkers for improved cancer detection and diagnosis; 3) the development of novel therapeutics for successful and comprehensive cancer treatment; and 4) establish and implement effect cancer prevention measures. Over the last five years, Hillman's 350 faculty members have published more than 4,500 publications in peer-reviewed journals.

More information

Comments Statistics

| | Public